HIV-ASSIST: Modifying ART With Hyperlipidemia
Modifying ART in the Presence of Hyperlipidemia: Using HIV-ASSIST

Released: June 09, 2023

Maunank Shah
Maunank Shah, MD, PhD

Activity

Progress
1
Course Completed

In this episode, Maunank Shah, MD, PhD, discusses using HIV-ASSIST to optimize treatment for both HIV and hyperlipidemia. Listen as he covers:

  • Hyperlipidemia and cardiovascular disease risk among people living with HIV
  • Recommendations for lipid screening for people living with HIV
  • Using HIV-ASSIST to support ART treatment decisions for people living with HIV with comorbidities
  • How HIV-ASSIST prioritizes certain ART agents in the setting of hyperlipidemia, including:
    • Deciding between bictegravir, doravirine, dolutegravir, raltegravir, and rilpivirine vs boosted protease inhibitors, including darunavir
    • Deciding between tenofovir disoproxil fumarate and tenofovir alafenamide or abacavir
  • How HIV-ASSIST incorporates drug‒drug interaction data from the University of Liverpool HIV Drug Interactions Checker and the DHHS guidelines when considering the use of statin therapy with ART
  • How HIV-ASSIST further incorporates drug resistance data from the Stanford HIV Drug Resistance Database